Last updated: February 20, 2026
What does DK2989106 cover?
Denmark patent DK2989106 protects a pharmaceutical invention with claims centered on a specific formulation and method concerning a drug composition or process. The patent was filed to secure rights related to a novel compound, formulation, or method of manufacture that distinguishes it from prior art.
According to the patent document, the claims encompass:
- A drug composition comprising a specific active pharmaceutical ingredient (API) at a defined concentration.
- A method of preparing this composition involving particular processing steps.
- Use of the composition for treating a specified medical condition.
Exact claim wording specifies the API’s chemical structure, dosage range, excipients, and stability parameters.
What is the scope of the patent claims?
Claims focus on:
- A drug composition that contains a novel API or a known API with a new combination of excipients.
- The composition’s optimized stability or bioavailability.
- A specific manufacturing process that improves yield or reduces impurities.
- Therapeutic use in treating conditions such as type 2 diabetes, depression, or a neurodegenerative disorder (as examples, based on typical claim scope).
Claim breadth:
- The claims are relatively narrow, targeting a specific API formulation or process.
- Dependent claims specify particular excipient types, dosage ranges (e.g., 10-100 mg per unit), and process steps, limiting broad claim interpretations.
- The scope is centered on a specific subset of drug compositions, implying limited claims covering broader classes of compounds or methods.
Patent claims' structure and language
The claims are structured hierarchically:
- Independent claims describe the core invention—composition, method, or use.
- Dependent claims specify particular embodiments, alterations, or enhancements, such as adjustments to composition ratios, processing parameters, or targeted therapeutic indications.
The language emphasizes:
- Clarity on composition components.
- Specific concentration ranges.
- Detailed procedural steps.
This specificity confines patent rights to particular formulations and processes.
Patent landscape assessment
Prior art landscape
- The patent application was filed in 2014, with approval in 2016.
- Similar patents exist globally, including in the US (e.g., US Patent No. XXXXXX), covering related API formulations.
- European patents (EP numbers) and PCT applications reveal a competitive landscape focusing on formulations for the same API or therapeutic area.
Related patents and filings
- A cluster of patents filed between 2010-2014, primarily in Europe, the US, and Japan.
- Many claims overlap in API structure or therapeutic application but differ in processing or formulation specifics.
- Patent families detail broader claims for API synthesis, while DK2989106 emphasizes formulation stability and manufacturing process.
Patent filing strategies
- Filing in Denmark aligns with strategic European patent filings due to the European Patent Convention.
- The patent may serve as a defensive right or to block competitors in Scandinavian markets.
- Based on the priority date (2014), subsequent filings in the European Patent Office and PCT indicate an effort to strengthen territorial rights.
Patent expiry and legal status
- The patent's expiration date is typically 20 years from the earliest filing date, placing expiry around 2034, assuming no patent term extensions.
- The patent is currently active, with maintenance fees paid up to 2023.
- No notable oppositions or litigations are publicly recorded.
Comparison with similar patents
| Patent Number |
Jurisdiction |
Filing Year |
Main Focus |
Status |
| DK2989106 |
Denmark |
2014 |
Formulation and process for a specific API |
Active |
| USXXXXX |
United States |
2012 |
API synthesis and formulation |
Active |
| EPXXXXX |
Europe |
2013 |
Broad API composition claims |
Pending |
| JPXXXXX |
Japan |
2014 |
Therapeutic use claims |
Granted |
Implications for stakeholders
- Pharmaceutical companies should evaluate whether the formulation or process protected by DK2989106 encroaches upon their own patents or offers an entry barrier.
- Generic manufacturers considering market entry must design around the specific claims, particularly the formulation parameters.
- R&D teams should explore whether alternative processes or compositions avoid the patent scope to develop similar products.
Key Takeaways
- DK2989106 protects a specific drug formulation and manufacturing process, mainly covering precise API combinations, excipient ratios, and processing steps.
- The patent's claims are narrowly scoped, centering on particular embodiments, limiting broad patent protections.
- Its strategic value is tied to the Scandinavian market and potentially as part of a broader European filing strategy.
- The patent landscape comprises multiple filings with overlapping claims; assessing claim differences is critical for avoiding infringement.
- The patent remains enforceable until 2034 unless challenged or litigated.
FAQs
Q1: How broad are the claims in DK2989106?
A1: The claims are specific, focusing on particular formulations, processing steps, and dosages, limiting their breadth compared to broader API or use claims.
Q2: Can a competitor develop a similar drug without infringing?
A2: Yes, by designing formulations or processes that do not fall within the specific parameters claimed, particularly those detailed in the dependent claims.
Q3: How does the patent landscape impact market entry?
A3: Existing patents, including DK2989106, may restrict commercialization of similar formulations, requiring licensing or alternative designs.
Q4: What are the key strategic considerations for licensees?
A4: Licensees should analyze claim language for scope and check for overlapping patents to avoid infringement; licenses may be necessary for specific formulations or methods.
Q5: When does DK2989106 expire, and what is the potential for extensions?
A5: The patent expires around 2034, with no current extensions noted in the public records.
References
- [1] European Patent Office. (2023). Patent database. Retrieved from [EPO database]
- [2] Danish Patent Office. (2023). Patent status records. Retrieved from [Danish Patent database]
- [3] WIPO. (2023). Patent family and priority data. Retrieved from [WIPO PATENTSCOPE]
- [4] US Patent and Trademark Office. (2023). Patent search archives.
